Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 57.5%

Neg 57.5% Neu 0% Pos 0%

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $18 to $15.